Page 3 - Decipher Prostate News Today

Veracyte, Inc. today announced that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary ... | February 1, 2023

11.09.2022 - Veracyte, Inc. (Nasdaq: VCYT) announced that new data from a Phase 3 trial of the multi-center, multi-national, randomized STAMPEDE platform protocol confirm the ability of the company’s Decipher Prostate Genomic Classifier to identify men with ... Seite 1

New data support continued expansion of the company's tests, including determining treatment prognosis in men with advanced prostate cancer Veracyte, Inc. (Nasdaq: VCYT) announced today that seven

A higher score on the Decipher assay increased the risk of biopsy upgrade nearly fourfold, according to a new study published as a preprint.

Decipher Test Clinically Validated as a Predictor of Overall Survival in Men with Prostate Cancer Decipher test validated in study of the practice-changing Phase 3 RTOG 96-01 clinical trial News provided by Share this article Share this article SAN DIEGO, Feb. 11, 2021 /PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, with a focus in urologic oncology specific to prostate and bladder cancers, today announced publication of ...